Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7821657 · 1 trial · 1 indication
AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria
AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria
| Arm | Type | Description |
|---|---|---|
| Part 1A: Dose Escalation | EXPERIMENTAL | Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts. |
| Part 1B: Backfill Cohorts | EXPERIMENTAL | Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A. |
| Part 1C: Dose Expansion/Optimization | EXPERIMENTAL | Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B. |
| Part 2A: Abbreviated Dose Escalation | EXPERIMENTAL | Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts. |
| Part 2B: Dose Expansion/Optimization | EXPERIMENTAL | Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A. |
| Name | Type | Description |
|---|---|---|
| RO7821657 | DRUG | Participants will receive RO7821657 as per the schedule described in the protocol. |
Inclusion Criteria: * Life expectancy estimated by the Investigator to be ≥12 weeks. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1. * Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are c...